Syngene Q2 FY26 Earnings Results

Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

 

Q2 FY26 Earnings Results:

• Revenue from Operations: ₹911 crore, up 2% YoY from ₹908 crore.

• Profit After Tax (PAT): ₹67 crore, down 37% YoY from ₹106 crore.

• EBITDA: ₹215 crore, down 18% YoY from ₹262 crore.

• EBITDA Margin: contracted to 23.2% from 28.8% YoY.

• Significant write-off of ₹27.7 crore due to foreign exchange fluctuations and additional ₹16.5 crore in pre-operating expenses for US biologics facility.

• Focus on contract research and manufacturing services as the single operating segment.

 

Management Commentary & Strategic Insights:

• Managing Director & CEO Peter Bains noted that revenue growth was driven by research services, which helped offset the anticipated inventory correction in biologics manufacturing.

• Company maintains annual revenue guidance for FY26.

• Received a contract for a global phase III clinical trial from a US-based biotech with patient recruitment in the US and India.

• Ongoing investment in biologics capabilities to support growth in new modalities.

 

 

Q1 FY26 Earnings Results:

• Revenue: ₹875 crore, up 11% YoY from ₹790 crore.

• PAT: ₹87 crore, up 14% YoY from ₹76 crore.

• EBITDA: ₹206 crore, up 19% YoY with margin at 25%.

• Improved operational performance including successful audits and regulatory approvals.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.